公开(公告)号：US20060275866A1

公开(公告)日：2006-12-07

申请号：US11268745

申请日：2005-11-07

申请人： Katherine Galvin ,  Maria Glucksmann ,  Martin Hodge ,  John Hunter ,  Laura Rudolph-Owen ,  Inmaculada Silos-Santiago ,  Nadine Weich

发明人： Katherine Galvin ,  Maria Glucksmann ,  Martin Hodge ,  John Hunter ,  Laura Rudolph-Owen ,  Inmaculada Silos-Santiago ,  Nadine Weich

IPC分类号： C07K14/705 ,  C07H21/04 ,  C12P21/06

CPC分类号： C07K14/705

摘要： The invention provides isolated nucleic acids molecules, designated 2871, 14926, 44576, 23992, 1983, 52881, 2398, and 52872 nucleic acid molecules, which encode novel G protein-coupled receptor family members that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 proteins, fusion proteins, antigenic peptides and anti-2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子，命名为2871,14926,4457,239992,1983,52881,2988和52872核酸分子，其编码编码新多肽的新型G蛋白偶联受体家族成员。 本发明还提供反义核酸分子，含有2871,14926,4576,23992,1983,52881,2398或52872核酸分子的重组表达载体，已经引入了表达载体的宿主细胞，以及非人转基因动物，其中 已经引入或破坏了2871,14926,44576,23992,1983,52881,2398或52872基因。 本发明还进一步提供了分离的2871,14926,4457,239992,1983,52881,2398或52872蛋白质，融合蛋白，抗原肽和抗-2871,14926,4457,23992,1983,52881,29898或52872抗体。 还提供了利用本发明组合物的诊断方法。

公开(公告)号：US20070037203A1

公开(公告)日：2007-02-15

申请号：US11583766

申请日：2006-10-19

申请人： Rosana Kapeller-Libermann ,  John Hunter ,  Rachel Meyers ,  Laura Rudolph-Owen ,  Rory Curtis ,  Peter Olandt ,  Fong-Ying Tsai ,  Katherine Galvin ,  Miyoung Chun ,  Mark Williamson ,  Inmaculada Silos-Santiago ,  Rajasekhar Bandaru

发明人： Rosana Kapeller-Libermann ,  John Hunter ,  Rachel Meyers ,  Laura Rudolph-Owen ,  Rory Curtis ,  Peter Olandt ,  Fong-Ying Tsai ,  Katherine Galvin ,  Miyoung Chun ,  Mark Williamson ,  Inmaculada Silos-Santiago ,  Rajasekhar Bandaru

IPC分类号： C12Q1/68 ,  C07H21/04 ,  A61K48/00 ,  C07K14/705

CPC分类号： C07K14/47 ,  A01K2217/05 ,  C12N9/1235

摘要： The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted. The invention still further provides isolated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 proteins, fusion proteins, antigenic peptides and anti-21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子，命名为21910,5663,55053,2504,15977,14760,25501,17903,3720,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,38555和593核酸 分子。 本发明还提供反义核酸分子，含有21910,5663,55053,2504,15977,14760,25501,17903,3700,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,3855的重组表达载体 和593个核酸分子，其中引入了表达载体的宿主细胞，以及非人类转基因动物，其中21910,5663,5553,2504,15977,14760,25501,17903,3720,21529,26176， 已经引入或破坏了18610,33217,21967，h1983，m1983,38555或593基因。 本发明还进一步提供分离的21910,5563,4560,25501,17903,3720,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,38555或593蛋白，融合蛋白， 抗原肽和抗-19910,563634,55053,2504,15977,14760,25501,17903,3720,21529,26176,26343,56638,18610,33217,21967，h1983，m1983,38555或593抗体。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US20070015201A1

公开(公告)日：2007-01-18

申请号：US11522789

申请日：2006-09-18

申请人： Maria Glucksmann ,  Inmaculada Silos-Santiago ,  Joseph Carroll ,  Katherine Galvin

发明人： Maria Glucksmann ,  Inmaculada Silos-Santiago ,  Joseph Carroll ,  Katherine Galvin

IPC分类号： C12Q1/68 ,  G01N33/567 ,  C07H21/04 ,  C12P21/06 ,  C07K14/705 ,  C07K16/28

CPC分类号： C07K14/47 ,  C07K14/705 ,  Y10T436/143333

摘要： The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子，命名为18636,2466,43238,1983,52881,29898,45449,50289,52872和26908核酸分子。 本发明还提供反义核酸分子，含有18636,2466,43238,1983,52881,29898,45449,502892,5282和26908核酸分子的重组表达载体，已经引入表达载体的宿主细胞和非人转基因 引入或破坏18636,2466,43238,1983,52881,2398,45449,50289,52872或26908基因的动物。 本发明还进一步提供了分离的18636,2466,43238,1983,52881,2398,45449,50289,52872或26908蛋白，融合蛋白，抗原肽和抗-18636,2466,43238,1983,52881,29898,45449,50289 ，52872或26908抗体。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US06359194B1

公开(公告)日：2002-03-19

申请号：US09288292

申请日：1999-04-08

申请人： Katherine Galvin ,  Dean A. Falb ,  Michael J. Donovan ,  Dennis Huszar ,  Michael A. Gimbrone, Jr.

发明人： Katherine Galvin ,  Dean A. Falb ,  Michael J. Donovan ,  Dennis Huszar ,  Michael A. Gimbrone, Jr.

IPC分类号： A01K67027

CPC分类号： C12N15/113 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/47 ,  C12N9/0065 ,  C12N9/0083 ,  C12N9/0089

摘要： The present invention is based on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF-&bgr; signaling pathways. Such transgenic mice may be used for screening compounds that may potentially useful for treating or preventing cardiovascular disease.

摘要翻译： 本发明基于显示特征性心血管疾病症状的转基因敲除纯合rchd534突变小鼠的产生和表型表征。 这种转基因敲除纯合rchd534突变小鼠是用于分析和表征rchd534蛋白参与心血管系统的发育和体内平衡以及TGF-β信号传导途径的组织特异性调节的有用模型。 这样的转基因小鼠可用于筛选可能潜在地用于治疗或预防心血管疾病的化合物。

公开(公告)号：US20050037946A1

公开(公告)日：2005-02-17

申请号：US10753267

申请日：2004-01-08

申请人： Nancy Stagliano ,  Aileen Healy ,  Susan Acton ,  Katherine Galvin ,  Mary Donoghue ,  Amelie Rodrigue-Way ,  James Tomlinson

发明人： Nancy Stagliano ,  Aileen Healy ,  Susan Acton ,  Katherine Galvin ,  Mary Donoghue ,  Amelie Rodrigue-Way ,  James Tomlinson

IPC分类号： C07K14/47 ,  A61K31/00

CPC分类号： C07K14/47

摘要： The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 and 2419 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.